Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of aggressive blood cancer called large B-cell lymphoma, confirmed by laboratory testing, where the cancer cells carry certain markers (CD19 and/or CD22), and who either had a partial response to their first round of standard chemotherapy, or had a complete response but had certain high-risk features when first diagnosed.
• People whose cancer has certain high-risk features, such as specific genetic changes in the cancer cells (including "double-hit" or "triple-hit" lymphoma confirmed by a specialist lab test), certain abnormalities on chromosome 11, a higher-risk score on standard cancer risk-scoring systems, specific protein markers on the cancer cells (CD5, MYC, or BCL2), a gene change called TP53, a specific cancer subtype identified by advanced genetic testing, or people whose cancer came back or did not respond well enough to previous treatment (confirm with trial site for full details on which combinations apply).
• People aged 18 to 85 years, of any gender.
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0–2).
• People whose doctors expect them to live for more than 3 months from the time they sign the consent form.
• People whose blood counts meet minimum levels — specifically, haemoglobin at or above a certain level (blood transfusions are allowed to help reach this), and adequate levels of infection-fighting white blood cells and platelets.
• People whose liver, kidneys, heart, and lungs are functioning well enough to meet specific measurement thresholds set out by the trial (confirm exact values with trial site).

Who may not be able to join:

• People who have previously received CAR-T cell therapy or any other type of genetically modified T-cell treatment.
• People who have had a severe allergic reaction to aminoglycoside antibiotics or similar medicines.
• People with a known HIV infection, an active hepatitis B infection that meets specific criteria, or any uncontrolled active infection currently requiring intravenous antibiotics (people who had active hepatitis B at diagnosis but brought it under control with ongoing antiviral treatment may still be considered — confirm with trial site).
• People whose liver or kidney function falls below the trial's required levels for reasons unrelated to blood cancer, based on specific blood test results (confirm with trial site).
• People who have had a heart attack, certain heart procedures, unstable chest pain, active heart rhythm problems, or other significant heart disease within the past 12 months.
• People with other serious medical conditions that the trial doctors believe could interfere with treatment or increase health risks, such as poorly controlled diabetes, active stomach ulcers, severe breathing or circulation problems, severe autoimmune disease, a condition present from birth affecting the immune system, or uncontrolled serious infection.
• People with a history of severe allergic reactions to any medicines required during the trial, or a history of severe allergic reactions to biological medicines (including certain antibiotics).
• People who are pregnant or breastfeeding, because the preparatory chemotherapy used in this trial carries potential risks to an unborn baby or infant.
• People who, in the trial doctors' judgement, are unlikely to be able to attend all required visits and follow-up appointments, or who are not willing or able to participate fully.
• People with a history of another cancer, unless they have been free of that cancer and have not received any cancer treatment for at least 3 years (exceptions may apply for certain non-serious skin cancers or early-stage cancers of the cervix, bladder, or breast — confirm with trial site).
• People who have received a live vaccine within the 6 weeks before starting the preparatory treatment phase.
• People who have had major surgery (other than a lymph node biopsy) within the past 14 days, or who are expected to need major surgery during the treatment period.
• People with any other serious physical or mental health condition, or significantly abnormal laboratory results, that the trial doctors believe would make participation unsafe or affect the reliability of the trial results.

Important: Always verify eligibility with the trial site directly before applying.